Joseph Ronald Mace MD
Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology
Physician
Join to View Full Profile
1201 5th Ave NSte 505Saint Petersburg, FL 33705
Phone+1 727-821-0017
Fax+1 727-502-8861
Dr. Mace is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 1999 - 2002
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1996 - 1999
University of Pennsylvania Health SystemResidency, Radiology-Diagnostic, 1994 - 1996
St Joseph's HealthInternship, Transitional Year, 1993 - 1994
SUNY Upstate Medical UniversityClass of 1993
Certifications & Licensure
FL State Medical License 2002 - 2027
NY State Medical License 1999 - 2004
MI State Medical License 1998 - 2003
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2014
Clinical Trials
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Publications & Presentations
PubMed
- 147 citationsDaratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a ra...Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau
The Lancet. Oncology. 2021-10-13 - 9 citationsA phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-...Jesus G. Berdeja, Tara K. Gregory, Edward A. Faber, Lowell L. Hart, Joseph R. Mace
American Journal of Hematology. 2021-01-09 - 11 citationsPhase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP ChemotherapyIan W. Flinn, Jack Erter, Davey B. Daniel, Joseph R. Mace, Jesus G. Berdeja
The Oncologist. 2019-08-01
Press Mentions
Lucio N. Gordan, MD Discusses Findings of Phase 3 Clinical Trial Supporting Advanced Treatments for Multiple Myeloma in National BroadcastApril 26th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
